Xbrane Biopharma AB (publ)
SSE:XBRANE.ST
2.085 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 238.729 | 57.618 | 11.533 | 6.821 | 0.6 | 112.953 | 20.771 | 2.49 | 0.433 | 0.19 | 0.19 | 0.991 |
| Cost of Revenue
| 224.774 | 16.576 | 12.217 | 4.37 | 18.271 | 15.907 | 15.829 | 6.621 | 0.257 | 0 | 0.099 | 1.245 |
| Gross Profit
| 13.955 | 41.042 | -0.684 | 2.451 | -17.671 | 97.046 | 4.942 | -4.131 | 0.177 | 0.19 | 0.091 | -0.254 |
| Gross Profit Ratio
| 0.058 | 0.712 | -0.059 | 0.359 | -29.452 | 0.859 | 0.238 | -1.659 | 0.408 | 1 | 0.48 | -0.256 |
| Reseach & Development Expenses
| 305.783 | 199.648 | 160.619 | 203.301 | 115.713 | 85.827 | 37.982 | 2.856 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 40.031 | 31.538 | 31.395 | 31.189 | 26.415 | 23.347 | 11.567 | 1.574 | 6.632 | 2.113 | 0.73 | 0 |
| Selling & Marketing Expenses
| -21.433 | 0 | 0 | 0 | 0.454 | 0.933 | 1.381 | 18.562 | 0 | 0 | 0 | 0 |
| SG&A
| 18.598 | 31.538 | 31.395 | 31.189 | 26.869 | 24.28 | 12.948 | 1.574 | 6.632 | 2.113 | 0.73 | 2.113 |
| Other Expenses
| -0.47 | -20.914 | -0.084 | -3.417 | -2.295 | -0.466 | -0.076 | -0.219 | -0.025 | 0.596 | 1.567 | 0 |
| Operating Expenses
| 324.381 | 210.272 | 191.93 | 231.073 | 140.287 | 107.518 | 48.416 | 28.973 | 8.935 | 2.709 | 2.297 | 0.579 |
| Operating Income
| -310.426 | -166.217 | -180.397 | -224.252 | -164.62 | -11.415 | -44.718 | -33.222 | -11.551 | -2.574 | -2.107 | -0.833 |
| Operating Income Ratio
| -1.3 | -2.885 | -15.642 | -32.877 | -274.367 | -0.101 | -2.153 | -13.341 | -26.647 | -13.575 | -11.119 | -0.84 |
| Total Other Income Expenses Net
| -11.602 | -2.296 | -2.829 | -1.774 | -1.417 | -2.643 | -1.461 | -0.185 | -0.294 | -0.053 | 0 | -0.001 |
| Income Before Tax
| -322.028 | -168.513 | -183.226 | -226.026 | -166.037 | -13.115 | -44.935 | -33.289 | -11.845 | -2.572 | -2.107 | -0.834 |
| Income Before Tax Ratio
| -1.349 | -2.925 | -15.887 | -33.137 | -276.728 | -0.116 | -2.163 | -13.368 | -27.326 | -13.563 | -11.119 | -0.842 |
| Income Tax Expense
| 66.144 | 3.713 | 7.786 | 0.766 | 1.437 | 0.121 | -1.244 | 0.02 | 2.769 | 0.004 | -0 | -0.001 |
| Net Income
| -388.172 | -172.226 | -191.012 | -226.792 | -167.474 | -13.236 | -44.935 | -33.289 | -11.845 | -2.572 | -2.107 | -0.834 |
| Net Income Ratio
| -1.626 | -2.989 | -16.562 | -33.249 | -279.123 | -0.117 | -2.163 | -13.368 | -27.326 | -13.563 | -11.119 | -0.842 |
| EPS
| -1.53 | -0.76 | -0.92 | -1.42 | -1.7 | -2.02 | -7.85 | -7 | -5.18 | -1.09 | -0.9 | -0.355 |
| EPS Diluted
| -1.53 | -0.76 | -0.92 | -1.42 | -1.7 | -2.02 | -7.85 | -7 | -5.03 | -1.09 | -0.9 | -0.355 |
| EBITDA
| -288.993 | -165.93 | -167.592 | -218.694 | -157.274 | -6.168 | -44.806 | -24.545 | -7.341 | -2.461 | -2.107 | -0.001 |
| EBITDA Ratio
| -1.211 | -2.88 | -14.532 | -32.062 | -262.123 | -0.055 | -2.157 | -9.857 | -16.936 | -12.979 | -11.119 | -0.001 |